BioTherapeutics' critical care therapies includes albumin which is primarly used as plasma-volume replacement therapy for the treatment of hypovolemia. Baxter is the only company to offer albumin in a flexible, plastic container. Other critical care therapies include Protein C for patients with severe congenital Protein C deficiency.
For additional resources, please click here.
| Product | Primary Uses | Product Description |
| FLEXBUMIN 25%, Albumin (Human) (US) | Plasma-volume replacement therapy for the treatment of hypovolemia | A sterile, nonpyrogenic preparation of albumin in a flexible single-dosage form for intravenous administration |
|
Human Albumin 200 g/l and Human Albumin 250 g/l (International) |
Plasma-volume replacement therapy for the treatment of hypovolemia | A sterile, nonpyrogenic preparation of albumin in a flexible single-dosage form for intravenous administration |
|
BUMINATE 25% Albumin (Human) and BUMINATE 5% Albumin (Human) (US) |
Plasma-volume replacement therapy for the treatment of hypovolemia | A sterile, nonpyrogenic preparation of albumin in a single-dosage form for intravenous administration |
|
HUMAN ALBUMIN 50 g/l BAXTER and HUMAN ALBUMIN 200 g/l BAXTER and HUMAN ALBUMIN 250 g/l BAXTER (International) |
Plasma-volume replacement therapy for the treatment of hypovolemia | A sterile, nonpyrogenic preparation of albumin in a single-dosage form for intravenous administration |
| CEPROTIN [Protein C Concentrate (Human)] (US) | For patients with severe congenital Protein C deficiency for the prevention and treatment of: For pediatric and adult use | 500 IU (5ml of SWFI) or 1000IU (10ml of SWFI) vial of CEPROTIN powder, one vial of Sterile Water for Injection (diluent) |
|
500 IU
Human Protein C and 1000 IU Human Protein C (International) |
Severe congenital Protein C deficiency and, | Powder and solvent for solution for intravenous injection |
|
Prothrombin Complex Human Steam Treated
(International) |
Bleeding and perioperative prophylaxis of bleeding in congenital and acquired deficiency of prothrombin complex coagulation factors. | Powder and solvent for solution for intravenous injection |
| Human plasma-derived Antithrombin (International) | For patients with a plasma antithrombin III (AT III) activity below 70% of normal for prophylaxis and treatment of thrombotic and thromboembolic disorders | Powder and solvent for solution or injection |
A sterile, nonpyrogenic preparation of albumin in a single-dosage
Read More [+]
For the treatment of severe congenital Protein C deficiency.
Please consult your local approved product labeling for prescribing information. Please note that not all products are licensed in all countries.